Scenario
Please read this scenario prior to answering the Question You are serving as the Lead Architect for
an enterprise architecture project team within a leading medical device manufacturer that
specializes in miniature devices. The latest product under development is a tiny wireless device that
can be implanted in the brain and can deliver a precise electric shock when the wearable Pain
Control Unit (PCU) detects an increase in stress induced by the onset of a migraine headache. This
technology will be a breakthrough in the treatment of this condition, and several competitors are
striving to be the first to introduce a product into the market. However, all of them must
demonstrate the effectiveness and safety of their products in a set of clinical trials that will satisfy
the regulatory requirements of the countries in the target markets. The Enterprise Architecture
group within the company has been engaged in an architecture development project to create a
secure networked collaboration system that will allow researchers at its product development
laboratories worldwide to share information about their independent clinical trials. The Enterprise
Architecture group is a mature organization that has been utilizing TOGAF for several years. They use
the TOGAF 9 ADM with extensions required to support current good manufacturing practices and
good laboratory practices in their target markets. Due to the highly sensitive nature of the
information that is managed, special care was taken to ensure that each architecture domain
included an examination of the security and privacy issues that are relevant for each domain. A
corresponding Security Architecture has been defined. The Executive Vice President for Clinical
Research is the sponsor of the Enterprise Architecture activity. She has stated that the changes to
the enterprise architecture for the new system will need to be rolled out on a geographic basis that
will minimize disruptions to ongoing clinical trials. The work will need to be done in stages and rolled
out in geographical regions. Refer to the Scenario You have been asked to recommend the approach
to identify the work packages that will be included in the Transition Architecture(s). Based on TOGAF
9, which of the following is the best answer?
A.
Determine the set of Solution Building Blocks required by identifying which Solution Building
Blocks need to be developed and which need to be procured. Eliminate any duplicate building
blocks. Group the remaining Solution Building Blocks together to create the work packages using a
CRUD matrix. Rank the work packages in terms of cost and select the most cost-effective options for
inclusion in a series of Transition Architectures. Schedule the roll out of the work packages to be
sequential across the geographic regions.
B.
Create an Implementation Factor Assessment and Deduction Matrix and a Consolidated Gaps,
Solutions and Dependencies Matrix. For each gap, identify a proposed solution and classify it as new
development, purchased solution, or based on an existing product. Group similar solutions together
to form work packages. Identify dependencies between work packages factoring in the clinical trial
schedules. Regroup the packages into a set of Capability Increments scheduled into a series of
Transition Architectures.
C.
Group the Solution Building Blocks from a Consolidated Gaps, Solutions and Dependencies Matrix
into a set of work packages. Using the matrix as a planning tool, regroup the work packages to
account for dependencies. Sequence the work packages into the Capability Increments needed to
achieve the Target Architecture. Schedule the rollout one region at a time. Document the
progression of the enterprise architecture using a state evolution table.
D.
Use a Consolidated Gaps, Solutions and Dependencies Matrix as a planning tool. For each gap
classify whether the solution is either a new envelopment, purchased solution, or based on an
existing product. Group the similar solutions together to define the work packages. Regroup the
work packages into a set of Capability Increments to transition to the Target Architecture taking into
account the schedule for clinical trials.